Multi-biomarker score model for predicting fatal outcomes in severe fever with thrombocytopenia syndrome: a multicenter cohort study

用于预测重症发热伴血小板减少综合征致命结局的多生物标志物评分模型:一项多中心队列研究

阅读:2

Abstract

BACKGROUND: Severe fever with thrombocytopenia syndrome (SFTS) is a rapidly progressive disease with high mortality. This study aims to identify mortality risk factors in SFTS and create a prognostic model for early high-risk patient identification. METHODS: A total of 301 SFTS patients were enrolled between May 2012 and July 2023 from nine clinical centers across the East China region. Using principal component analysis and cox regression, we identified independent risk factors for mortality and constructed the multi-biomarker score model (1 point was assigned when age ≥60 years, AST/ALT ratio ≥2.23, BUN ≥5.6 mmol/L, ALP ≥ 68 U/L, or ALB <33.3 g/L). RESULTS: Of the 301 patients with SFTS, 57 (18.9%) experienced fatal outcomes during hospitalization. The risk of mortality escalated with each additional point on the multi-biomarker score, with a HR of 2.04 (95% CI, 1.60-2.61). Patients were stratified into low (0-1), intermediate (2-3), and high (4-5) risk groups based on their multi-biomarker scores. Notably, those in the high-risk category were at an over eightfold increased risk of mortality (HR, 8.59; 95% CI, 2.63-28.05). High scores (4-5) were also predictive of adverse outcomes, including secondary bacterial infection, meningitis, ICU admission, heart failure, respiratory failure, and renal failure. The receiver operating characteristic (ROC) curve analysis for the multi-biomarker score revealed an AUC of 0.769 (95% CI, 0.632-0.787), suggesting a cutoff value above 3 as the threshold for optimal discrimination. CONCLUSIONS: SFTS patients with more than three of the following criteria-age ≥60 years, AST/ALT ratio ≥2.23, BUN ≥5.6 mmol/L, ALP ≥68 U/L, or ALB <33.3 g/L-show a significantly elevated mortality risk.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。